See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.
Morning Overview on MSN
Magic mushroom therapy just jumped closer to FDA approval
The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for ...
George Goldsmith is the Chairman, CEO and Co‑Founder of COMPASS Pathways (NASDAQ:CMPS). Mr. Goldsmith’s early training and experience was a multi-disciplinary blending of cognitive psychology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results